FUSCC Refractory TNBC Platform Study (FUTURE2.0)

This is a Phase II, open-label, Single-center platform study research based on molecular subtypes to explore precision therapy in refractory triple-negative breast cancer.

Trial Details

NCT ID
NCT05749588
Phase
PHASE2
Sponsor
Fudan University
Status
RECRUITING
Cancer Type
HER2 Positive Breast Cancer
Interventions
  • A1: SHR-A1811
  • A2: SHR-A1811 with Camrelizumab with famitinib
  • B1: TROP2 ADC
  • B2: TROP2 ADC with Camrelizumab
  • C1: SHR-A1811
  • C2: SHR-A1811 with BP102
Locations (sample)
  • Shanghai, China|31.22222,121.45806

Key Eligibility Criteria

  • Female aged ≥18 years;
  • TNBC invasive breast cancer confirmed by histology (specific definition: ER \<1% positive tumor cells by immunohistochemistry are defined as ER neg…
  • Progression after at least one prior therapeutic regimens for advanced/metastatic TNBC
  • At least one measurable lesion according to RECIST 1.1 (conventional CT scan ≥20 mm, spiral CT scan ≥10 mm, measurable lesion has not received radi…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find HER2 Positive Breast Cancer Trials on Trialify →